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Abstract
We assessed the effects of two different single-dose anti-Chlamydia pecorum (C. pecorum)
vaccines (containing either Major Outer Membrane Protein (3MOMP) or Polymorphic Mem-
brane Protein (Pmp) as antigens) on the immune response of a group of wild koalas. Both
vaccines elicited a systemic humoral response as seen by the production of anti-chlamydial
IgG antibodies in more than 90% of vaccinated koalas. A mucosal immune response was
also observed, with an increase in Chlamydia-specific mucosal IgG and/or IgA antibodies in
some koalas post-vaccination. Both vaccines elicited a cell-mediated immune response as
measured by the production of the cytokines IFN-γ and IL-17 post-vaccination. To deter-
mine the level of protection provided by the vaccines under natural conditions we assessed
C. pecorum infection loads and chlamydial disease status of all vaccinated koalas pre- and
post-vaccination, compared to a non-vaccinated cohort from the same habitat. The MOMP
vaccinated koalas that were infected on the day of vaccination showed significant clearance
of their infection at 6 months post-vaccination. In contrast, the number of new infections in
the PMP vaccine was similar to the control group, with some koalas progressing to disease.
Genotyping of the ompA gene from the C. pecorum strains infecting the vaccinated animals,
identified genetic variants of ompA-F genotype and a new genotype ompA-O. We found that
those animals that were the least well protected became infected with strains of C. pecorum
not covered by the vaccine. In conclusion, a single dose vaccine formulated with either
recombinant PmpG or MOMP can elicit both cell-mediated and humoral (systemic and
mucosal) immune responses, with the MOMP vaccine showing clearance of infection in all
infected koalas. Although the capability of our vaccines to stimulate an adaptive response
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and be protective needs to be fully evaluated, this work illustrates the necessity to combine
epitopes most relevant to a large panel of variable strains with an efficient adjuvant.
Introduction
Disease caused by the obligate intracellular bacterial pathogen, Chlamydia, is a significant
threat to the ongoing survival of the koala. Combined with habitat destruction, motor vehicle
injuries and dog attacks, this threat has driven many koala populations in Australia to the
point of near extinction in some areas [1, 2].
Amongst the 11 species in the genus Chlamydia currently recognised, [3–5], C. pecorum is
an important veterinary pathogen that causes debilitating ocular and urogenital infections in
koalas with clinical signs such as conjunctivitis, kerato-conjunctivitis, rhinitis, cystitis, infertil-
ity and sterility [2]. To date, once a clinical chlamydial infection is detected in a koala, a 4–6
week course of antibiotic such as chloramphenicol is usually administered to clear the infec-
tion. Unfortunately, such practice has negative impacts on koala welfare as each treated animal
needs to be kept in captivity for the length of the treatment. A successful anti-chlamydial vac-
cine would allow better management of the disease in the koala population with minimal
impact on koala welfare.
Developing an efficient chlamydial vaccine has proven challenging in all animal species to
date, as both an efficient delivery system (adjuvant) and specific immunogenic antigen(s) need
to be combined to promote both humoral and cell-mediated immune responses [6–8]. Indeed,
upon invasion of the mucosal lining by chlamydia, the innate immune system is activated, fol-
lowed by induction of the adaptive immunity pathways in order to limit the spread of the
infection and protect against recurrent infections. The immune response to chlamydia thus
includes production of pro-inflammatory cytokines, followed by maturation of T cells into
both CD4 and CD8 T cells (recognizing specific MHC-presented chlamydial antigens) and
activation of B cells that will produce specific anti-chlamydial antibodies [6, 8, 9]. The cytokine
IFN-γ plays a key role in both the innate and the adaptive immune responses against chlamyd-
ial infections by contributing to inhibiting the growth of the bacteria chlamydia and activating
the T-cell immune response to ultimately trigger protection against re-infections [10]. Similar
to IFN-γ, IL-17 appears elevated in koalas with C. pecorum disease, compared to healthy
infected animals, and previous work with C. muridarum suggests that IL-17 might play a role
in clearing the infection by synergistically working with IFN-γ to inhibit chlamydial growth
[11–13]. Finally, murine vaccine studies have suggested that IL-17 is also important for protec-
tion against new infections [14]. Therefore, both cytokines IFN-γ and IL-17 seem to play cru-
cial roles in the initiation and establishment of an anti-chlamydia immune response, which
one would expect to see similarly modulated by a successful anti-chlamydial vaccine.
A major antigen candidate for a chlamydial vaccine is the chlamydial major outer mem-
brane protein (MOMP). MOMP contains four variable hydrophilic domains exposed to the
surface on the outer membrane of chlamydia and allows adhesion to the mannose receptor of
the host cell, during the initial phase of infection [15, 16]. MOMP has been used in several clin-
ical trials, in different animals, with encouraging results [17–20], eliciting a T cell-mediated
response together with IFN-γ production [17, 21–23]. Other antigenic proteins including poly-
morphic membrane proteins (Pmps) have also been evaluated in mice [24]. Pmps are a group
of membrane bound surface-exposed chlamydial proteins [25]. Pmps contain an auto-trans-
porter adhesion domain important for the initial phase of chlamydial infection by contributing
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to attachment to the mucosal cell membranes possibly via the epidermal growth factor recep-
tor [26]. Each chlamydial genome encodes a variable number of Pmp proteins differentially
expressed throughout the chlamydial developmental cycle. For C. trachomatis, PmpG is the
most immunogenic protein in murine vaccine models [27, 28], while PmpD was identified as
very immunogenic for C. abortus and C. psittaci [29, 30]. The C. pecorum genome appears to
encode at least nine PmpG family proteins [31]. PmpG1 and to a lesser extent PmpG 9 were
under positive selection in koala strains, with immune pressure being a likely driver of this
selection in this host [31].
Our previous work in koalas showed that a single dose vaccine formulation with a tri-adju-
vant (TriAdj) combined with a cocktail of three MOMP antigens was safe and triggered both
humoral and cellular immune responses in healthy, Chlamydia-negative, female koalas in cap-
tivity, and a small subset of non-infected wild koalas [17, 23]. In the current study, we extended
this work with the use of the TriAdj vaccine combined to a new C. pecorum antigen, PmpG,
and compared this newly formulated vaccine with the 3MOMP vaccine.
Materials and methods
Cloning, expression and purification of recombinant koala C. pecorum
PmpG protein
The adhesin domain (also referred as GGAI domain in the literature) of koala C. pecorum
PmpG (aa 27 to aa 520 of the PmpG1 gene) was PCR amplified using specific primers, kPmg-F
(5’-AATGAGCTCGAGACTATCCCCATCCCATCTAAAAATTTC-3’)kPmg-R (5’-TTA
GCGGCCGCTTATTTTCTAAGGTGACTTGCTGATTG-3’), to generate a PCR product with
5’Sac1 and 3’Not1 restriction sites (underlined in the sequences). The Sac1/Not1 double
digested PCR product was subsequently cloned into Sac1/Not1 double digested pET28a
expression vector (Invitrogen), in frame with the N-terminal poly-histidine (His) tag to pro-
duce a final protein of 538 aa, including the 504 aa fragment of kPmpG. The pET-His-kPmpG
expression vector was transformed into BL21 (DE3) competent E. coli cells (Bioline) and
grown in LB media with 100 μg/mL ampicillin at 37˚C. His-kPpmG expression and purifica-
tion was conducted as per ‘The Expressionist’ protocol for non-soluble proteins (Qiagen).
Briefly, protein expression was induced at OD600 of 0.4–0.6, by adding 1 mM IPTG (Astral
Scientific) for 7 h. Cells were harvested by centrifugation and resuspended in lysis buffer I (50
mM phosphate buffer pH 7.0, 8M urea, 50 μL Bacterial Protease Inhibitor Cocktail (Sigma-
Aldrich)), and 1 mg/mL lysozyme (Sigma-Aldrich). Cells were lysed by sonication on ice and
the clear lysate incubated with TALON affinity resin (Ni-NTA, Qiagen) at RT for 1 h with gen-
tle mixing. After repeated washes (50 mM phosphate buffer pH 7.0, 300 mM NaCl, and 8M
urea) of the resin on a gravity column, the His-kPmpG protein (which will be referred as
PmpG protein from now on) was eluted with 50 mM phosphate buffer pH 7.0, 300 mM NaCl,
150 mM imidazole and 8 M urea, at pH 5.6, then pH 4.5. Protein was visualized by western
blot using anti-His antibody (Life Technologies Australia Pty Ltd) and IRDye1 800CW Don-
key anti mouse (LICOR), purity assessed by SDS-PAGE (Bio-rad), and protein concentrations
determined with Micro BCA Protein Assay Kit (Pierce). A schematic of the PmpG protein
used in the vaccine is provided in S1 Fig.
Expression and purification of C. pecorum MOMP-A, -F and G
recombinant proteins
Koala recombinant proteins from three different serotypes (MOMP-A,—F, and—G) previ-
ously described and genotyped by Kollipara et al. [32] were purified according to the published
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protocol of with modifications as follows: (A) cell lysis were performed by sonication on ice
with addition of lysozyme; (B) after binding of His-MOMP proteins to the Ni-NTA beads
(Qiagen), washes and elution were performed on a gravity column to prevent contamination
of the eluate with affinity beads. A schematic of the MOMP-A,—F, and—G proteins used in
the vaccine is provided in S1 Fig.
Vaccine formulation
Endotoxin content was determined for each purified recombinant protein using the LAL
Chromogenic Endotoxin Quantitation Kit (Pierce) according to the manufacturer’s protocol.
Quantities of endotoxin determined were as follow: 2.63 EU/mL for the 3MOMP proteins,
and 0.54 EU/mL for the PmpG protein.
TRiAdj 3MOMP and PmpG vaccines were prepared according to a previously published
protocol by Garlapati et al. [33]. A final concentration of 150 μg of 3MOMP proteins (50 μg
each MOMP protein) or 150 μg of PmpG protein were co-formulated at a ratio 1:2:1 with
PCEP (250 μg; poly[di(sodium carboxylatoethylphenoxy)]-phosphazene), IDR1002 (500 μg)
and polyI:C (250 μg) in PBS, all provided by VIDO-intervac (University of Saskatchewan, Sas-
katoon, SK, CA). For each vaccine, 500 μl injection doses were then aliquoted in endotoxin-
free sterile glass vials (Thermofisher) surrounded with aluminium foil to protect from the
light, and stored at -20˚C until injection.
Experimental groups of koalas, immunization schedule, sampling
For this study, 63 koalas located in the Moreton bay region, Queensland, Australia (and part of
the Moreton Bay Rail Link project by the Queensland Government Department of Transport
and Main Roads) were selected after thorough veterinary health assessment by experienced
wildlife veterinarians. The koalas were enrolled in the trial according to the following criteria:
koalas were older than 1 year old (breeding age) and showed no clinical signs of chlamydial
disease (chlamydiosis) such as ocular or UGT discharge or severe inflammation, and negative
Clearview1 Chlamydia test. The selected koalas were randomly assigned into three groups:
group ‘3MOMP’ vaccine was vaccinated with the 3MOMP TriAdj vaccine (3MOMP vaccine),
group ‘PmpG’ vaccine was vaccinated with the PmpG TriAdj vaccine (PmpG vaccine) and a
control group was non-vaccinated. All koalas were sampled prior to immunisation (21 animals
in the 3MOMP vaccine cohort, 21 animals in the PmpG vaccine cohort) and then between 5 to
7 months post immunisation (when capture was judged possible and safe–referred to as the”
6-month post-vaccination” time point here). Peripheral blood mononuclear cells (PBMCs)
were purified from blood samples according to Mathew et al (2013; [34]). Serum was separated
from coagulated blood by centrifugation at 1000g for five min at RT and stored at -20˚C for
further analysis. Ocular and UGT swabs were collected for mucosal immunity studies in 1.5
mL eppendorf tubes containing 1 mL PBS plus protease inhibitor (ROCHE) and frozen at
-20˚C. For C. pecorum infection screening, dry ocular and UGT swabs were collected and
stored at -20˚C until genomic DNA extraction.
All procedures were approved by the University of the Sunshine Coast (USC) Animal Ethics
Committee (Animal ethics number AN/A/13/80) and by the Queensland Government (Scien-
tific Purposes Permit, WISP11532912). The trial was performed under the Australian Pesti-
cides and Veterinary Medicines Authority Permit PER 725.
Koala C. pecorum-specific IgG and IgA ELISA
ELISAs were performed according to Carey et al. [35] with modifications. Briefly, 96-well
plates (medium-high binding, SIGMA) were coated overnight at 4˚C with His-MOMP, or
MOMP and PmpG vaccines in wild koalas: Immune response, protection, clearance
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His-PmpG proteins (1 μg per 50 μl, per well), or 1 μg of semi-purified C pecorum strain G EBs
(purified according to [35]) in carbonate-bicarbonate buffer. After washing and blocking in
0.05% Tween-PBS (PBS-T) with 5% skim milk, all subsequent incubations were carried out at
37˚C for 1 hour separated by 3 washes with PBS-T. Following blocking with milk, 1:3 serially
diluted sera were added to the wells. Initial dilution for all sera was 1:100. All swab (mucosal)
samples were initially diluted 1:2, then, serially diluted 1:2. For IgG ELISAs, the secondary
antibody incubation was performed using sheep anti-koala IgG diluted 1:8000 in PBS-T, fol-
lowed by a final incubation with HRP-conjugated donkey anti-sheep IgG (1:10000, ABCAM).
For IgA ELISAs, the second incubation used a rabbit anti-koala IgA antibody (see IgA Section)
at 1:2000 and the final incubation used HRP-conjugated goat anti-rabbit IgG (1:10000,
ABCAM). TMB substrate in citrate buffer, prepared as per the manufacturer (Sigma-Aldrich),
was added to each well and, after 20 min of incubation at RT, reactions were stopped by adding
the same volume of 1M H2SO4. Optical density was determined at 450nm. All samples were
tested in duplicate.
End point titres (EPT) were calculated as the inverse of the dilution value at which the
tested serum is no longer giving a positive signal using Graph Pad Prism. The cut off values
were calculated as the average of the ‘no sample’ control values added to the standard deviation
multiplied by two. The ‘no sample’ control corresponded to the addition of PBS-T instead of
the first sera or swab sample after milk blocking, all other incubations remaining the same.
Preparation of rabbit anti-koala IgA
Purified recombinant koala IgA heavy chain constant region was produced and purified by
affinity and size exclusion chromatography by Protein Expression Facility (PEF; University of
Queensland, Brisbane, Australia) and subsequently used to immunize rabbits. Following
serum isolation from two independent rabbits, specific polyclonal anti-IgA antibodies were
affinity purified (Mimotopes, The Peptide Company, Victoria, Australia). Purified anti-koala
IgA was tested and validated by ELISA and western blot (data not shown). In this study, anti-
koala IgA was used at 1/2000 dilution in the ELISA.
Koala lymphocyte stimulation assay. RNA extraction, reverse
transcription and qRT-PCR assays
Experiments to assess gene expression of koala IFN-γ, Il-17 and IL-10 were performed as pre-
viously described by Mathew et al. [11, 36] with GAPDH as internal control. As such, purified
peripheral blood mononuclear cells (PBMCs) from 3MOMP or PmpG vaccinated koala blood
samples were diluted to a concentration of 2×106 cells/mL and stimulated for 12 hours with
UV inactivated semi-purified C. pecorum G strain EBs at a final dilution of 1:10. PBMCs were
suspended in 1 mL of Trizol reagent (Invitrogen, Australia), RNA extracted and cDNA synthe-
sized. All reactions were carried out in a final volume of 20 μL, containing 5 μL of cDNA sam-
ple, 1 μL of 10 μM forward and reverse primers and 1X QuantiTect SYBR1 Green PCR mix
(Qiagen) as previously described [11, 36]. All samples were tested in duplicates.
Screening for C. pecorum infection by qPCR
Pre- and post-immunization ocular and urogenital tract (UGT) dry swabs were screened for
the presence of C. pecorum infections by 16S rRNA gene C. pecorum quantitative PCR modi-
fied from Marsh et al. [37]. The C. pecorum 16S 204 bp fragment (RT-Cpec -F: 5'-AGTCGAA
CGGAATAATGGCT-3', RT-Cpec-R: 5'-CCAACAAGCTGATATCCCAC-3'; IDT) was sub-
cloned into pGem-T Easy (Promega) and amplified with M13 universal primers to generate a
M13-Cpec-16S fragment of 465 bp. Serial dilutions of the M13-Cpec-16S fragment were used
MOMP and PmpG vaccines in wild koalas: Immune response, protection, clearance
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to produce a standard curve by mixing 5 μl of diluted fragment with RT-Cpec-F and RT-Cpec-
R primers (1μM final) and 1X QuantiTect SYBR1 Green PCR mix (Qiagen) in a final volume
reaction of 20 μl. Cycling conditions were 95˚C- 15 min, followed by 35 cycles of 94˚C- 15 sec,
57˚C- 15 sec, 72˚C- 30 sec, and a final amplification cycle of 72˚C, 10 min. Diluted C. pecorum
G type strain served as a positive control while dH2O was used as negative control. A detection
level of 100 copies/μL was established and values below this result were reported as ‘Below
Detection Level’ (BDL). All samples were tested in duplicate.
C. pecorum ompA sequencing, alignment and phylogeny
Genetic diversity in the MOMP-encoding ompA gene of C. pecorum strains detected in the
vaccinated koalas was determined by amplifying the near full length ompA gene (1140 bp)
using conventional PCR. Where multiple PCR positive samples were available for a koala,
the sample with the highest qPCR load was selected for ompA gene sequencing. The primers
used in this reaction were ompA-F (50-ATGAAAAAACTCTTAAAATCGG-30) and ompA-R
(50-TTAGAATCTGCATTGAGCAG-30). PCR conditions were a single cycle of initial denatur-
ation at 95˚C for 10 min, 40 cycles of denaturation at 95˚C for 30 s, primer annealing at 57˚C
for 40 s, primer extension at 72˚C for 90 s, followed by a final extension at 72˚C for 7 min. For
koalas presenting a qPCR load less than 3000 16S rDNA copies/μL, a second round of amplifi-
cation was attempted on the purified product from the first PCR. All ompA sequences were
determined by Sanger sequencing of the Forward and Reverse ompA PCR products (AGRF,
Brisbane, Australia).
Phylogenetic analysis on 10 koala C. pecorum ompA sequences identified in this study was
performed with the Geneious 9.1 software (http://www.geneious.com; [38]). Briefly, forward
and reverse chromatograms for each ompA gene were aligned, and a consensus sequence was
obtained and trimmed so that all sequences were of the same length. The obtained ompA
sequences were aligned using ClustalW (as implemented in Geneious 9.1), and also translated
into amino acid sequences and aligned. DnaSp v5.1 [38] was used to analyse sequence poly-
morphisms such as total number of polymorphic sites and haplotypes, as well as the number of
non-synonymous (dn) and synonymous (ds) substitutions per site (Jukes-Cantor corrected). A
mid-point rooted Bayesian phylogenetic tree for the 24 ompA sequences, including the 10
koala C. pecorum ompA sequences generated in this study, and 13 previously described koala
C. pecorum ompA sequences [39], and bovine C. pecorum E58 ompA sequence (accession num-
ber CP002608), was constructed with MrBayes (as implemented in Geneious 9.1). Parameters
included HKY +I+G model with four MCMC chains with 1 000 000 generations, with sub-
sampling frequency of 1 000, and 10 000 trees discarded as burn-in. The bovine C. pecorum
E58 ompA sequence was used as an out-group. The 10 koala C. pecorum ompA sequences (M1,
M11, M8, M14, M17, C11, C12, C13, P4, P8) from this study are available in Genbank under
accession numbers KX388198 (M1), KX388199 (C13), KX388200 (C12), KX388201 (P8),
KX388202 (M11), KX388203 (C11), KX388204 (M8), KX388205 (P4), KX388206 (M14),
KX388207 (M17).
Statistics
All statistical analyses were performed using GraphPad Prism version 5 (GraphPad Software,
LaJolla, CA, USA) and IBM SBSS statistics 22. All IgG ELISA data and cytokine levels pre-
sented include the mean of 21 koalas for each cohort. Statistical significance of these data pre-
and post-vaccination were determined by using Wilcoxon signed rank tests with the p values
set at p<0.05, p<0.01, p<0.005, p<0.001. To evaluate the contingency between
MOMP and PmpG vaccines in wild koalas: Immune response, protection, clearance
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decrease in chlamydial load and vaccination, and development of chlamydiosis and vaccina-
tion, we used Fisher’s exact test with the same p value setting as previously stated.
Results
Systemic antibody responses post-vaccination with the vaccines
Antigen-specific antibody responses from animals in both vaccine cohorts (3MOMP and
PmpG) were evaluated by ELISA, using purified recombinant MOMP or PmpG proteins (S1
Fig), and sera collected from koalas at the pre-vaccination and 6 months post-vaccination time
points (MPV; Fig 1). For the 3MOMP vaccine, each MOMP antigen was evaluated separately.
The 3MOMP vaccine showed a significant increase in IgG end-point titre (EPT) for both
MOMP-G (P = 0.009) and MOMP-F (P = 0.0016) antigens (Fig 1A and 1C). However, we
detected low EPT values and no significant difference in serum IgG for anti-MOMP-A anti-
bodies pre- and post-vaccination. All three recombinant MOMP proteins were produced
and purified using a similar protocol. When examined individually, koalas vaccinated with
3MOMP showed a wide range of antibody response, with 57% koalas (12/21) exhibiting a
modest 2-fold increase in EPT 6 months post-vaccination for MOMP-G and 67% koalas (14/
21) exhibiting a 10-fold increase in EPT for MOMP–F (Fig 1D). Interestingly, 47% of koalas
(10/21) showed an increased EPT for both MOMP-F and–G (see koala M1 and M19 for exam-
ple), while 38% only seroconverted for one of the antigens. PmpG vaccinated koalas also
showed a significant increase in EPT 6 months post-vaccination (Fig 1E; p<0.0001), with 57%
Fig 1. Systemic antibody responses post-vaccination with the 3MOMP and Pmp vaccines. End point titre (EPT) of anti-MOMP and anti-PmpG
IgGs in sera from pre-vaccination and 6 months post-vaccination koalas determined by ELISA. IgG titres against purified recombinant MOMP-F and
MOMP-G proteins are shown for the 3MOMP vaccine for the whole cohort (panels A and C). For PmpG vaccine, recombinant purified PmpG protein
was tested (panels E and F) with sera from PmpG vaccine koalas. Panels A, C, and E show a representation of the results as Log EPT for the whole
3MOMP vaccine or PmpG vaccine cohorts, pre- and 6 months post-vaccination (mean values are indicated). Panels B, D, F show the EPT values
obtained for each koala in each vaccine cohort. MPV stands for Months Post-Vaccination. P values were calculated using Wilcoxon matched-pairs
signed rank t-test are documented in the results section.
https://doi.org/10.1371/journal.pone.0178786.g001
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of koalas (12/21) giving a 10-fold increase in EPT (Fig 1F). Together, the data show that both
3MOMP and PmpG vaccines elicited an antibody response in a total of 19 koalas out of 21
(90.5%) or 21 koalas out of 21 (100%) respectively, with PmpG vaccine exhibiting the highest
EPT values overall.
Reactivity of 3MOMP and PmpG immunized koala sera to whole inactivated C. pecorum
G EBs was also assessed using ELISA (Fig 2). Both vaccine cohorts developed a significant
increase in IgG titre to C. pecorum, 6 months post-vaccination (Fig 2A and 2C; 3MOMP vac-
cine: p = 0.019; PmpG vaccine: p<0.0001). In the 3MOMP vaccinated cohort, 33% koalas (7/
21) developed a 2-fold or higher increase in EPT post-vaccination (Fig 2B). The PmpG vaccine
cohort showed a higher ratio with 91.9% koalas (13/21) exhibiting a 10-fold or more increase
in EPT values after vaccination (Fig 2D). Altogether, these results demonstrated that both
3MOMP and PmpG vaccines can trigger a humoral immune response in more than 90% of
Fig 2. Systemic IgG antibody responses to C. pecorum EBs post-vaccination with the 3MOMP and Pmp vaccines. Specific IgG antibody
response to whole Chlamydia pecorum serovar G elementary bodies (EBs) in sera following immunization with 3MOMP and PmpG vaccines. Serums
from vaccination day or 6 months post-vaccination were assayed for antigen-specific IgG responses by ELISA using whole EBs. (A) and (C) represent
EPT and statistics for 3MOMP and PmpG vaccinated cohorts respectively. (B) and (D) show the EPT obtained for each koala in each cohort. MPV
stands for Months Post-Vaccination. P values (Significance was analysed using Wilcoxon matched-pairs signed rank t-test) are documented in the
results section.
https://doi.org/10.1371/journal.pone.0178786.g002
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vaccinated koalas and that the IgG antibodies produced as a result of both vaccinations can
recognize native epitopes present on intact C. pecorum EBs.
Mucosal immune responses in vaccinated koalas
To assess the induction of mucosal immunity by both 3MOMP and PmpG vaccines, we mea-
sured the IgG and IgA antibody titres in ocular and urogenital (UGT) swabs, pre- and post-
immunization, using ELISA assays with recombinant MOMP and PmpG purified proteins
(Fig 3). Despite large variations of EPT values amongst koalas within both cohorts, a mucosal
immune response was observed with both vaccines in a sub-group of the vaccinated koalas.
Indeed, the 3MOMP vaccine increased the EPT titre for anti-MOMP IgA by 10 to 100-fold, at
both ocular (5/10 koalas, p = 0.0625) and UGT sites (4/10 koalas; p = 0.125; Fig 3A). Similarly,
the PmpG vaccine triggered a 10 to 100-fold increase in EPT values for IgA antibodies at the
UGT (4/10 koalas; p = 0.25) or the ocular sites (5/10 koalas; p = 0.0625) post-vaccination (Fig
3B). Evaluation of an IgG response at the mucosal sites of koalas vaccinated with the 3MOMP
vaccine showed a more modest but significant 2-fold increase or higher in mucosal anti-
MOMP IgG in both ocular (57.1%; 12/21) and UGT samples (50%; 5/10) 6 months post-vacci-
nation (Fig 3C, P = 0.009 and P = 0.0195 respectively). In 10 koalas where both ocular and
UGT samples were measured, 50% presented an increase at both sites (data not shown). For
the PmpG vaccine, although statistically non-significant, 42% (8/19) and 63% (7/11) of koalas
showed a 2-fold or higher increase in either ocular or UGT mucosal IgG recognising recombi-
nant PmpG 6 months post-vaccination (Fig 3D; P = 0.0681 and P = 0.0781 respectively).
Overall, our data demonstrated that both 3MOMP and PmpG vaccines did elicit a mucosal
response in some koalas by triggering production of 3MOMP and PmpG-specific IgG and IgA
antibodies at ocular and UGT sites.
Cytokine expression in vaccinated animals
Previous research suggests that the host defence mechanisms to chlamydial infections involves
secretion of IFN-γ and IL-17 [9]. We therefore measured the chlamydia-specific response of
these two cytokines pre- and post-vaccination with 3MOMP and PmpG vaccines using RT-
qPCR on purified circulating PBMCs, after in vitro stimulation with UV inactivated EBs (Fig
4). Both 3MOMP and PmpG vaccines elicited a significant increase in IFN-γ and IL-17 in EB-
stimulated PBMCs (Fig 3A and 3B respectively). For koalas vaccinated with 3MOMP, 57.1%
(8/14) showed an increase in IFN-γ P = 0.0495) and 78.6% (11/14) showed an increase in IL-
17 (p = 0.017) post-vaccination (Fig 4A, panel right and left respectively). A total of 8 koalas
out of 14 exhibited a 2-fold or more increase in IFN-γ gene expression post-vaccination, while
IL-17 gene expression increased more than 2-fold in 9/14 koalas post-vaccination. Overall,
50% of 3MOMP vaccinated koalas displayed a 2-fold or more increase in both IL17 and IFN-γ.
Similarly, 86.6% (13/15; p = 0.015) of the PmpG vaccinated koalas exhibited an increase in
IFN-γ and 100% (15/15, p = 0.0015) in IL-17, post-vaccination (Fig 4B, panels left and right
respectively). IFN-γ expression increased by more than 2-fold in 66.7% of koalas post-vaccina-
tion while IL-17 expression increased by 2-fold or more in 80% of the vaccinated koalas. Simi-
lar to 3MOMP vaccinated koalas, 50% of PmpG vaccinated koalas displayed a 2-fold or more
increase in both IFN-γ and IL-17 expression post-vaccination.
Interestingly, for both 3MOMP and PmpG vaccines, we did not observe any correlation
between the antibody response and cytokine production, as some koalas exhibiting a strong
humoral response showed a poor cell-mediated response and vice versa (data not shown).
However, post-vaccination expression levels of IFN-γ and IL -17 were significantly higher in
some of the PmpG vaccinated koalas compared to the 3MOMP vaccinated cohort. Indeed,
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Fig 3. Mucosal specific IgG and IgA antibody response to MOMP and PmpG vaccines. Mucosal specific
IgG and IgA antibody response to MOMP and PmpG antigens in ocular and UGT swabs samples following
immunization with 3MOMP and PmpG vaccines. Swabs from vaccination day or 6 months post-vaccination
(ocular and UGT) were assayed for antigen-specific IgG responses by ELISA using purified recombinant
proteins MOMP and PmpG. Right and left panels represent the EPT values and statistics obtained for MOMP-
specific IgAs at the ocular and UGT sites respectively, for the 3MOMP vaccinated cohort. Fig 3 B represents
MOMP and PmpG vaccines in wild koalas: Immune response, protection, clearance
PLOS ONE | https://doi.org/10.1371/journal.pone.0178786 June 2, 2017 10 / 23
with the PmpG vaccine, 33% koalas had a 200-fold or more increase in IL-17 and 33% koalas
had a 90-fold or more increase in IFN-γ, and only one koala showed such a strong increase in
both cytokines. Although biological variation amongst koalas was observed, these results
showed that both 3MOMP and PmpG vaccines induce production of both host defence IFN-γ
and IL-17 cytokines, with the PmpG vaccine triggering a more robust increase in expression of
both cytokines compared to the 3MOMP vaccine.
the EPT values and statistics obtained for PmpG-specific IgAs at the ocular or UGT sites for the PmpG
vaccinated cohort. Panels (C) and (D) show the IgG EPT obtained at either mucosal site (ocular and UGT, left
and right panels respectively) in 3MOMP or PmpG vaccine cohort respectively. MPV stands for Months Post-
Vaccination. P values obtained using Wilcoxon matched-pairs signed rank t-test are documented in the
results section.
https://doi.org/10.1371/journal.pone.0178786.g003
Fig 4. IFN-γ and IL-17 expression in vaccinated koalas. Gene expression of IFN-γ and IL-17 cytokines pre and post immunization. Gene expression of
cytokines IFN-γ and IL17 were quantified using RT-qPCR assays on PBMCs from vaccinated koalas, stimulated with C. pecorum EBs. Data represent the
mean-fold change expression of either 3MOMP (panel A) or PmpG (panel B) vaccinated koalas relative to house-keeping gene GAPDH, for IFN-γ and
IL17 respectively. Significance was analysed using Wilcoxon matched-pairs signed rank t-test.
https://doi.org/10.1371/journal.pone.0178786.g004
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Chlamydia infectious loads in koalas, pre- and post-vaccination
Although all of the koalas in our study group were clinically healthy at the time of vaccination,
we assessed the presence of C. pecorum in ocular and UGT swabs for each koala pre- and post-
vaccination using qPCR (Table 1). The qPCR loads were compared with a control group of 21
koalas from the same geographical area, which received no vaccination. At the time of vaccina-
tion, both non-vaccinated (Table 1) and 3MOMP (Table 2) vaccinated cohorts had koalas with
a chlamydial infection but no sign of clinical disease: 9.5% non-vaccinated koalas (2/21; C5,
C12), and 28.6% of 3MOMP koalas (6/21; M2, M8, M10, M11, M14 ad M17). The PmpG
(Table 3) cohort had no koala (0/21) presenting a chlamydial infection at the time of vaccina-
tion. We then determined the chlamydial infection load at the 6-month time point in all
cohorts. For the non-vaccinated group, four koalas out of 21 (19%) had a load that increased at
the 6-month time point compared to the time point 0 [2/21 koalas increased at both ocular
and UGT sites (C11 and C13), and three new infections (C6, C11 and C13; qPCR load were
below detection level (BDL) at time point 0)]. During the 6-month trial time, koala C12 pro-
gressed to chlamydiosis and was treated with antibiotics, clearing the chlamydial infection as
shown by a below detection level qPCR result at the 6-month time point (Table 1). Koalas C11
and C13 developed chlamydiosis by the 6-month time point, accompanied by a high qPCR
Table 1. Chlamydia infection in the non-vaccinated cohort.
Non -Vaccinated
Ocular Loads UGT Loads Chlamydiosis during the 6-month trial Chlamydiosis post the 6-month trial
Months post-vaccine Months post-vaccine
0 6 0 6
C1 BDL BDL BDL BDL N N
C2 BDL BDL BDL BDL N Y
C3 BDL BDL BDL BDL N N
C4 BDL BDL BDL BDL N N
C5 BDL BDL 176 242 N N
C6 BDL 518 BDL BDL N N
C7 BDL BDL BDL BDL N N
C8 BDL BDL BDL BDL N N
C9 BDL BDL BDL BDL N N
C10 BDL BDL BDL BDL N N
C11 BDL 1212 BDL 10800 Y N
C12 BDL BDL 439 BDL Y N
C13 BDL 25964 BDL 2552 Y N
C14 BDL BDL BDL BDL N N
C15 BDL BDL BDL BDL N N
C16 BDL BDL BDL BDL N N
C17 BDL BDL BDL BDL N N
C18 BDL BDL BDL BDL N N
C19 BDL BDL BDL BDL N Y
C20 BDL BDL BDL BDL N N
C21 BDL BDL BDL BDL N N
Infection with C. pecorum was assessed in the non-vaccinated control cohort using our C. pecorum 16S qPCR assay. Loads obtained are indicated for each
koala in copies/μL of sample, pre and post-vaccination. BDL stands for Below Detection Level, and corresponds to <100 copies/ μL. Clinical disease status
were recorded for each koala whether it occurred during the trial or during the 3 months past the trial period.
https://doi.org/10.1371/journal.pone.0178786.t001
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load at both sampling sites (Table 1). In the 3MOMP vaccine cohort, while 6 koalas had a posi-
tive load at the time of vaccination, all loads were decreased 6 months post-vaccination (6/21
koalas; 4 ocular sites, 4 UGT sites). This was significantly different to the non-vaccinated
group where no decrease in chlamydial load was observed in infected koalas (p = 0.048).
Importantly, we observed no occurrence of new infections in the 3MOMP vaccine cohort as
opposed to the non-vaccinated group that showed three new infections (Table 2). In the
PmpG vaccine cohort, 3 koalas (P8, P9 and P11) showed an increase in Chlamydia load post-
vaccination (3/21 koalas; 2 ocular sites, 2 UGT sites), corresponding to 3 new infections
(Table 3). The incidence of new infections in the PmpG vaccine cohort was similar to the non-
vaccinated cohort (3/21 koalas newly infected in each cohort). During the 6-months of our
trial, no koala in the vaccinated cohorts were reported with chlamydial disease.
However, while our main assessment period for the vaccine was 6 months post-vaccination,
we were able to make additional clinical observations up to 9 months post-vaccination (Tables
1–3, right column in table). At that time, an additional number of koalas developed chlamy-
diosis (UGT site) in each cohort: two koalas from the non-vaccinated group, three koalas from
the 3MOMP vaccine group and two koalas from the PmpG vaccine group. None of these
koalas had shown a positive C. pecorum qPCR load previously.
Table 2. Chlamydia infection in the 3MOMP vaccine cohort.
3MOMP Vaccine
Ocular Loads UGT Loads Chlamydiosis during the 6-month trial Chlamydiosis post the 6-month trial
Months post-vaccine Months post-vaccine
0 6 0 6
M1 BDL BDL BDL BDL N Y
M2 224 BDL BDL BDL N N
M3 BDL BDL BDL BDL N N
M4 BDL BDL BDL BDL N N
M5 BDL BDL BDL BDL N N
M6 BDL BDL BDL BDL N N
M7 BDL BDL BDL BDL N N
M8 BDL BDL 337 278 N N
M9 BDL BDL BDL BDL N N
M10 BDL BDL 228 BDL N N
M11 590 BDL 186 BDL N N
M12 BDL BDL BDL BDL N Y
M13 BDL BDL BDL BDL N N
M14 219 BDL 284 BDL N N
M15 BDL BDL BDL BDL N N
M16 BDL BDL BDL BDL N N
M17 193 BDL BDL BDL N N
M18 BDL BDL BDL BDL N Y
M19 BDL BDL BDL BDL N N
M20 BDL BDL BDL BDL N N
M21 BDL BDL BDL BDL N N
Infection with C. pecorum was assessed in the 3MOMP vaccine cohort using our C. pecorum 16S qPCR assay. Loads obtained are indicated for each koala
in copies/μL of sample, pre and post-vaccination. BDL stands for Below Detection Level, and corresponds to <100 copies/ μL. Clinical disease status were
recorded for each koala whether it occurred during the trial or during the 3 months past the trial period.
https://doi.org/10.1371/journal.pone.0178786.t002
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Altogether, our data showed that the 3MOMP and PmpG vaccines have different outcomes
regarding protection and clearance of chlamydial infections. New infections were observed in
both non-vaccinated and PmpG cohorts at both ocular and UGT sites, suggesting that the
PmpG vaccine failed to provide adequate protection against new infections in two animals. In
contrast, the 3MOMP vaccine seemed to be responsible for the clearing of six existing infec-
tions, and the absence of new infections. This vaccine might be efficient in clearing and possi-
bly protection against chlamydia infections. However, two koalas in the non-vaccinated group
and PmpG vaccine group, and three in the 3MOMP vaccine group developed new infections
leading to chlamydiosis between the 7th and 9th months post-vaccination suggesting that the
immune response triggered by the 3MOMP vaccine is short lasting.
Chlamydial clearance, mucosal IgA, Genotyping of C. pecorum strains
infecting koalas in the trial
Although we observed that vaccination with both 3MOMP and PmpG vaccines elicited a
humoral and cell-mediated immune response, the outcomes of chlamydial clearance and pro-
tection against new infections differed between the vaccines. We hypothesized that such differ-
ences might be due to (a) koala variations in the immune response to vaccination, or (b) that
Table 3. Chlamydia infection in the PmpG vaccine cohort.
PmpG Vaccine
Ocular Loads UGT Loads Chlamydiosis during the 6-month trial Chlamydiosis post the 6-month trial
Months post-vaccine Months post-vaccine
0 6 0 6
P1 BDL BDL BDL BDL N N
P2 BDL BDL BDL BDL N N
P3 BDL BDL BDL BDL N N
P4 BDL BDL BDL BDL N Y
P5 BDL BDL BDL BDL N N
P6 BDL BDL BDL BDL N N
P7 BDL BDL BDL BDL N N
P8 BDL 1292 BDL 2290 N N
P9 BDL BDL BDL 230 N N
P10 BDL BDL BDL BDL N N
P11 BDL 167 BDL 346 N N
P12 BDL BDL BDL BDL N Y
P13 BDL BDL BDL BDL N N
P14 BDL BDL BDL BDL N N
P15 BDL BDL BDL BDL N N
P16 BDL BDL BDL BDL N N
P17 BDL BDL BDL BDL N N
P18 BDL BDL BDL BDL N N
P19 BDL BDL BDL BDL N N
P20 BDL BDL BDL BDL N N
P21 BDL BDL BDL BDL N N
Infection with C. pecorum was assessed in the PmpG vaccine cohort using our C. pecorum 16S qPCR assay. Loads obtained are indicated for each koala in
copies/μL of sample, pre and post-vaccination. BDL stands for Below Detection Level, and corresponds to <100 copies/μL. Clinical disease status were
recorded for each koala whether it occurred during the trial or during the 3 months past the trial period.
https://doi.org/10.1371/journal.pone.0178786.t003
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C. pecorum strains with genetically variable MOMP and PmpG proteins to those included in
the vaccines might be circulating in our wild koala population. We first compared the immu-
nologic characteristics of each infected and diseased koala (data not shown). Regarding the
IgG or cell-mediated factors, we could not identify any consistent pattern that the presence or
absence of one or more immune factor could be responsible for the lack of protection in the
vaccinated koalas or koalas that developed chlamydial disease 9 months post-vaccination.
However, when the chlamydia levels and disease status post-vaccination were compared with
the mucosal IgA production in each koala, we identified that all koalas with a decreased C.
pecorum load post-vaccination also produced IgA with EPT values between 8<EPT<153 (Fig
5A). The koalas that had an increased C. pecorum load or were found diseased post-vaccination
showed no sign of IgA production in response to vaccination, except for one koala (P11) with
a high level of anti PmpG-IgA pre- and post-vaccination. Therefore, this data suggests that
production of anti-chlamydial IgA in response to 3MOMP vaccination might be associated
with a decrease in C. pecorum load in infected animals, although further studies would be
required.
We then determined which C. pecorum strains were present in the koalas in this trial popu-
lation by sequencing the near-full length ompA gene for each infected koala. Previous work
suggested that the dominant ompA genotypes carried by strains circulating in South East
Queensland are C. pecorum F and G [39]. Our vaccine contained recombinant protein made
from the three C.pecorum strains, A, F and G. We attempted to perform PCR-amplification
and sequencing of the ompA gene for each positive koala sample (previously shown in Table 1)
but were only able to obtain a PCR product and reliable sequence data for 10/21 koala samples.
Fig 5. Comparison of chlamydia and disease status with mucosal IgA, alignment and phylogenetic analysis of the new ompA genotypes in
infected koalas. (A) Infection and disease status was assessed and compared with mucosal IgA in koalas pre- and post-vaccination. (B) Alignment of the
new MOMP variants from strains infecting the koalas in the present vaccine trial including the previously described ompA F and F’ subtypes. (C) Bayesian
phylogenetic analysis of the 24 ompA sequences, including the 10 koala C. pecorum ompA sequences generated in this study, and 13 previously
described koala C. pecorum ompA genotypes. The C. pecorum E58 ompA sequence was used as an out-group. Posterior probabilities are displayed in
the tree nodes.
https://doi.org/10.1371/journal.pone.0178786.g005
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The sequenced 900bp ompA fragments were compared with all other ompA genes from all
strain types and subtypes previously identified in koalas, and also ompA from a reference strain
of C. pecorum identified in Australian livestock, E58. Out of the 10 ompA sequences analysed
from koalas in our study population, we identified 8 different ompA types. When translated
into the corresponding MOMP proteins, alignment with MOMP-F and -F’ clearly showed a
majority of non-synonymous mutations in the variable domain 4 (VD4) of the MOMP pro-
teins (Fig 5B). Surprisingly, the ompA sequence from two koalas (M14 and M17) showed a sig-
nificant diversity compared to the ompA sequences from the other koalas, suggesting that they
were infected with a different chlamydial strain. Phylogenetic analysis revealed that the C.
pecorum koala strains from this population segregated in two distinct, well-supported clades
(Fig 5C). Both koalas, M17 and M14, had a C. pecorum strain distinct from the strains detected
in other koalas, which clustered in a clade together with the livestock C. pecorum E58 strain
(Clade 1). M17 and M14 C. pecorum strains had one synonymous SNP, with M14 identical to
the E58 strain. The rest of the isolates all segregated to form Clade 2 together with C. pecorum
F strain and F’ subtype. A difference of 12 nucleotides (nt) in the ompA gene (1% of the gene)
has been proposed to define a new strain (39). As the differences in these ompA genes fluctu-
ated from 8 to 10 nt, we concluded that the koalas in our population were infected with vari-
ants of the F chlamydial strain. However, the difference between each koala ompA sequences
previously reported and the M17 and M14 ompA sequences varied from 84 to 175 nt, repre-
senting more than 7% divergence. We thus propose that M17 and M14 constitute a new koala
ompA genotype O (ompA-O), based on the current naming system [31, 40].
Discussion
In this study, we analysed the immune responses and protective effects of two different anti-
chlamydial vaccines delivered as a single dose in a wild population of koalas at 6 months post-
vaccination. We first demonstrated that both vaccines elicited a humoral response by inducing
the production of anti-chlamydial IgG antibodies in more than 90% of vaccinated koalas. This
systemic response to vaccination coincided with a mucosal response observed in some koalas
that showed an increase in IgG and/or IgA post-vaccination at ocular and UGT sites. Second,
both vaccines were capable of eliciting a cell-mediated immune response via increased produc-
tion of the two key cytokines, IFN-γ and IL-17. However, both vaccines displayed some differ-
ences in their ability to trigger the expected immune response: 3MOMP was a better stimulant
of the mucosal immune response, while PmpG resulted in the production of a higher level of
cytokines. Third, we assessed the chlamydial loads of all vaccinated koalas pre- and post-
vaccination, compared to a non-vaccinated cohort from the same geographical region. The
3MOMP vaccinated koalas that were infected on the day of vaccination showed a clearance of
their infection by 6 months post-vaccination, compared to the non-vaccinated infected koalas
that did not clear their infection and some of which also progressed to disease. Finally, we
identified genetic variants of C. pecorum in the geographical region of this koala population.
These strains had non-synonymous mutations in the immunogenic domains of MOMP.
These genetic variations might explain differential outcome of the vaccines on protection and
clearing of the disease, as they were different to the variants used in our vaccines.
We used two different antigens, MOMP and PmpG, and found no major differences in the
resulting immune responses observed between both vaccinated cohorts. Interestingly, some
animals showed a high anti-Chlamydia IgG titre prior to vaccination which did not correlate
with a current infectious chlamydia load, as determined by PCR, suggesting that these animals
had been previously naturally infected with Chlamydia and still contained residual anti-chla-
mydial antibodies. The presence of these antibodies did not appear to prevent either vaccine
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from triggering an immune response in vaccinated koalas. However, the vaccines showed a
difference in their outcome regarding clearing of existing infections and protection against
new ones. While the effect of our PmpG vaccine on clearance is still unknown, as we had no
infected koalas at the time of vaccination in that cohort, it failed to prevent new infections by 6
and 9 months post-vaccination (5 koalas out of 21 developing a new infection). This suggests
that, unfortunately, although immunogenic, the PmpG vaccine did not elicit the correct type
or strength of response required for ongoing protection from new infections under natural
conditions. This result is a little surprising as, in other chlamydial species, Pmp proteins have
been described as dominant antigenic targets for T-cell immune responses, and have been
reported to be immunogenic and protective against chlamydial reinfections in mice [14, 27,
28, 41, 42]. The selection of only one type of PmpG protein from one C. pecorum strain
included in the vaccine might be an explanation. Indeed, the PmpG genes that are under posi-
tive selection in a specific strain are the most likely to encode proteins with antigenic regions
capable of eliciting an immune response to a broader range of strains when included in a vac-
cine [43]. We previously identified nine PmpG genes in the C. pecorum genome [44, 45].
Amongst these nine PmpG genes, PmpG1 and 9 are under positive selection with pmpG1 hav-
ing the highest polymorphism [31]. Although we chose PmpG1 for this vaccine, it is possible
that PmpG9 or a combination of both would have been more potent in protecting against new
infections. Importantly, recent vaccine trials have combined several Pmps of variable polymor-
phism to give rise to efficient vaccines [27, 28, 42]. This suggests that selecting and including
several immunodominant C. pecorum PmpG proteins could be an option to provide a range of
epitopes for both T cell recognition and antigen presentation in our koala population with var-
iable MHC backgrounds, and further allow development of an adaptive immune response.
The 3MOMP vaccine clearly demonstrated a level of protection against current infection
and also some protection initially, at least, against new infections as evidenced by the observa-
tion of no new infections in the first 6 months post-vaccination compared to the non-vacci-
nated control group. However, two koalas developed new infections between 6 and 9 months
post-vaccination. This suggests that the adaptive immune response induced by the 3MOMP
vaccine is not long lasting or might be too specific for some C. pecorum strains. This suggests a
need to introduce more divergence in the vaccine epitopes in the future by selecting a larger
number of MOMP proteins with multiple strain variations.
Systemic and mucosal B and T cell-mediated immunity have been shown to be necessary to
elicit the adaptive immune response and provide protection against C. trachomatis infections
particularly in the mouse model [46–49]. In line with these findings, in addition to inducing a
C. pecorum-specific systemic immunity, vaccination of wild koalas with 3MOMP and PmpG
vaccines triggered mucosal immunity. However, the EPT values for anti-chlamydial IgA and
IgG were quite low in both UGT and ocular samples, for both vaccines. If such an immune
response was sufficient to clear C. pecorum infections such as in the 3MOMP vaccine, they
appear insufficient in the case of the PmpG vaccine. The route of immunization can determine
tissue-tropism of the immune cells and generate immune responses in various tissues (48).
Combined routes of immunization via intramuscular and intranasal delivery can further
induce systemic and mucosal immunity in minipigs infected with C. trachomatis [49]. The
adjuvant used in our study has been shown to be effective in intranasal delivery [50]. There-
fore, a double immunization of koalas via muscular and mucosal routes (nasal or genital)
might be the solution to boost the vaccine effect we already observed at the mucosal site by
eliciting a stronger, and potentially longer lasting, immune response and triggering mucosal
resident B and T cell-mediated immune responses.
All 3MOMP vaccinated koalas infected with C. pecorum at the time of vaccination cleared
their infection by 6 months post-vaccination. In contrast, none of the non-vaccinated infected
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koalas naturally cleared their infection, with some koalas even further progressing to disease. It
appears that this multi-epitope vaccine could be suitable to trigger the adaptive immune sys-
tem and provide cross-protection against antigenic variants required to clear C. pecorum infec-
tions in our wild population. Our data analysis suggested that production of IgA might be
associated with clearance of natural infections. The role of IgA in chlamydial infections
remains controversial. Indeed, while the absence of IgA in IgA-deficient mice seems to have
no effect on clearance of primary or secondary infections, other studies have reported the
effect of anti-MOMP IgA (from either vaccination with a MOMP vaccine or adoptive transfer)
on reducing chlamydial infections in mice [46, 47, 51]. Thus, although our data supported a
role for IgA in lowering chlamydial burden in koalas, further experiments are required to fully
elucidate the role of mucosal immunity in chlamydial infections.
Alongside humoral immunity, cell-mediated immunity is essential to fight chlamydial
infection. The importance in IFN-γ produced by CD4 T cells for protective immunity against
chlamydial infection has been demonstrated previously for C. trachomatis and C. muridarum
[7]. In C. pecorum, previous experiments showed a strong expression of IFN-y in koalas with
chlamydial infections, suggesting the same cytokine mechanisms as other chlamydial species
[36]. In addition, the Th17 cells contribute to host protective immunity against bacterial path-
ogens and IL-17 secreted from Th17 cells was associated with protection against C. muridarum
[52, 53]. Both 3MOMP and PmpG vaccines elicited a significantly increased expression of
both IFN-γ and IL-17, post-vaccination.
Mechanisms of protection against chlamydia infections after vaccination have been investi-
gated in other members of the genus. Indeed, recent experiments highlighting the role of cell-
mediated immunity and IFN-γ production on protecting against chlamydial infection post-
vaccinations. Although the role of IFN-γ has been well studied for C. trachomatis, and three
mechanisms proposed including the up-regulation of nitric oxide synthase, the down regula-
tion of the transferrin receptors for iron transport, or the inhibition of indoleamine 2,3-dioxy-
genase, these mechanisms have not yet been analysed in for animal C. pecorum infections [54].
Similarly, recent work on mice immunized with a vaccine containing a MOMP chimeric pro-
tein exhibiting selected T-cell and B-cell epitopes reduced shedding and immunopathology
associated with production of IFN-γ, IL-17 and IL-13 [42]. Production of TNF-α has also been
shown to participate in the clearance of chlamydial infection, potentially via up regulation of
IFN-β, NK cells or neutrophils [55]. Our results here with C.pecorum infection in koalas con-
firms that production of IFN-γ plays a role in clearance and protection. In addition, IgA has
also been suggested to be involved in protection against chlamydia. It has recently been
reported that vaccinated minipigs produced a strong genital secretory IgA response and this
correlated with protection against a live challenge in this model [49]. Again, our data here for
the koala model suggest that mucosal IgA levels do correlate with protection. At this stage, we
are unsure of the relative importance of these two immune mechanisms for protection in the
koala / C.pecorum natural situation.
In our koala cohorts, we identified eight C. pecorum ompA haplotypes from 10 C. pecorum
samples from infected koalas. Among these eight haplotypes, six were phylogenetically related
to genotype F’ and two were identical to C. pecorum strains previously identified in sheep, cat-
tle and koalas [31, 40]. Importantly, all the variant strains exhibited mutations resulting in
non-synonymous amino acid changes located mostly in the variable domain 4 (VD4) of the
resulting MOMP protein. As the VD4 domain is considered the most immunogenic domain
in the MOMP protein [39, 56], we hypothesize that non-synonymous changes in the amino-
acid content of this domain would lead to modifications of the overall structure of the MOMP
protein, inducing changes in the structural epitopes. As a consequence, the repertoire of anti-
bodies established with the 3MOMP vaccine might have a limited recognition of the variants
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of MOMP proteins expressed on C. pecorum naturally infecting strains in our koala popula-
tion, ultimately reducing the protective effects of the vaccine.
In conclusion, we have shown that recombinant PmpG protein is immunogenic, similar
to recombinant MOMP, and can elicit systemic and mucosal humoral and cell-mediated
immune responses with production of specific anti-chlamydial IgG and IgA antibodies. In
addition, the 3MOMP vaccine showed clearance of infection in six koalas suggesting that an
appropriate and adequate immune response can be elicited by vaccination. However, we also
identified a few koalas (2/21) that developed chlamydial disease in the 3MOMP and PmpG
vaccine cohorts, similar to the non-vaccinated group, after longer time periods (Refer to
Table 1, right columns, for chlamydiosis status of each koala in the trial). This suggests that
the vaccines were potentially short lasting. Analysis of the C. pecorum strains by ompA geno-
typing revealed a large genetic diversity of the ompA strains amongst infected koalas in our
trial. This might account for the reduced efficiency of the vaccine as all strains exhibited non-
synonymous mutations in the VD4 domain of ompA, known to contain T and B cell epitopes.
Although the capability of both vaccines to stimulate an adaptive response and be protective
needs to be fully evaluated, this work illustrates the necessity to combine epitopes most rele-
vant to a large panel of variable strains with an efficient adjuvant.
Supporting information
S1 Fig. Schematic of the MOMP-A, MOMP-F, MOMP-G and PMpG proteins included in
the 3MOMP and PmpG vaccines. Numbering indicates the amino acid number in the full
length protein. His corresponds to the hexa-histidine tag that consists of 6 histidine residues
located at the N-terminus of the recombinant MOMP and PmpG proteins.
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